|This Slide: #9 of 100|
Slide #9. Boston Scientific — IoGyn, Inc.
Boston Scientific (NYSE:BSX)
Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire IoGyn, Inc., a pre-commercial stage company. The transaction is expected to close within days. IoGyn has developed and received U.S. Food and Drug Administration (FDA) clearance for the Symphion System, a next generation system for hysteroscopic intrauterine tissue removal including fibroids (myomas) and polyps. This acquisition enables the pairing of the Symphion System with the Boston Scientific Genesys HTA System for abnormal uterine bleeding, to create a compelling set of gynecologic surgery products.
Boston Scientific is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical fields. Co.'s businesses include: Endoscopy, which develops and manufactures devices to diagnose and treat gastrointestinal and pulmonary conditions; Urology and Pelvic Health, which develops and manufactures devices to treat various urological and pelvic conditions; Cardiac Rhythm Management, which develops and manufactures implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; and Neuromodulation, which develops and manufactures devices to treat various neurological movement disorders and manage chronic pain.
Boston Scientific SEC Filing Email Alerts Service
Open the BSX Page at The Online Investor »
Strong Buy (3.87 out of 4)
(ranked higher than approx. 77% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite